Form 4: Arrowhead Pharmaceuticals CEO Sells Shares Under 10b5-1 Trading Plan

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 11,520 shares of common stock on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On January 2, 2025, Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, sold 11,520 shares of common stock.
• The sale was executed under a 10b5-1 trading plan.
• The shares were sold at a weighted average price of $19.05, with individual transactions ranging from $18.76 to $19.60.
• Following the transaction, Anzalone directly owns 3,764,252 shares of Arrowhead Pharmaceuticals, Inc.
• A portion of the disposed shares were related to the partial disposition of RSUs to satisfy tax withholding obligations.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales by an executive. The use of a 10b5-1 plan suggests the sale was pre-planned and doesn't necessarily reflect a negative outlook on the company.

Industry Context

Sales by executives are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on inside information at the time of the transaction.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The partial disposition of RSUs to satisfy tax obligations is a normal part of executive compensation.

Key Dates